Gene expression profiling analysis of hepatocellular carcinoma

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Kong, Deyong ^a   Chen, Heming ^b   Chen, Weiqun ^a,c   Liu, Shuiyi ^c   Wang, Hui ^a   Wu, Tangwei ^a   Lu, Hongda ^a,c   Kong, Qingzhi ^a,c   Huang, Xiaodong ^a,c   Lu, Zhongxin ^a,c  

^a CENTRAL HOSPITAL OF WUHAN   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Wuhan Institute of Medical Sciences   (China)

Author keywords

Bioinformatics method; Gene expression profiling; Hepatocellular carcinoma

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; AMODIAQUINE; ANISOMYCIN; BAMBUTEROL; BIOLOGICAL MARKER; DOBUTAMINE; DORZOLAMIDE; FLUOROCURARINE; LEVOBUNOLOL; MEVINOLIN; MOLINDONE; N (4 AMINOBUTYL) 5 CHLORO 2 NAPSYLAMIDE; ORPHENADRINE; OXYBUPROCAINE; PROTEIN TYROSINE KINASE; PYRVINIUM EMBONATE; RAUWOLSCINE; THAPSIGARGIN; TICARCILLIN; TIRATRICOL; TRIFLURIDINE; UNCLASSIFIED DRUG; SMALL MOLECULE TRANSPORT AGENT;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; FOCAL ADHESION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE POOL; GENE TARGETING; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; PARTIAL HEPATECTOMY; SIGNAL TRANSDUCTION; CANCER PATIENT; CANCER SURGERY; GENE EXPRESSION; GENE IDENTIFICATION; GENE ONTOLOGY; GENETIC ANALYSIS; RECURRENCE RISK; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84887349705     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-44     Document Type: Article

References (27)

1. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y, Nat Genet 2000 24 245 250 10.1038/73448 10700176 (Pubitemid 30132191)
2. Towards global control of liver cancer? Stuver SO, Semin Cancer Biol 1998 8 299 306 10.1006/scbi.1998.0079 9870036 (Pubitemid 28550387)
3. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Ghebranious N, Sell S, Hepatology 1998 27 383 391 10.1002/hep.510270211 9462635 (Pubitemid 28081051)
4. Sex hormone dependency of diethylnitrosamineinduced liver tumors in mice and chemoprevention by leuprorelin. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A, Jpn J Cancer Res 2001 92 249 256 10.1111/j.1349-7006.2001.tb01089.x 11267934 (Pubitemid 32288286)
5. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, Boussahmain C, Cormier KS, Fox JG, Cancer Res 2007 67 11536 11546 10.1158/0008-5472.CAN-07- 1479 18089782
6. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M, Science 2007 317 121 124 10.1126/science.1140485 17615358 (Pubitemid 47056470)
7. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T, Gastric Cancer 2005 8 124 131 10.1007/s10120-005-0315-x 15864720 (Pubitemid 40655522)
8. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR, Ann Oncol 2008 19 353 358 10.1093/annonc/mdm448 17962206 (Pubitemid 351201719)
9. The R Development Core Team, R: A Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing 2010 Available at [ http://www.lsw.uni-heidelberg.de/users/christlieb/teaching/ UKStaSS10/R-refman.pdf ] (accessed 20 September 2013)
10. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Irizarry RA, Hobbs B, Collin F, BeazerBarclay YD, Antonellis KJ, Scherf U, Speed TP, Biostatistics 2003 4 249 264 10.1093/biostatistics/4.2.249 12925520
11. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, Bioinformatics and Computational Biology Solutions Using R and Bioconductor (Statistics for Biology and Health Series) New York: Springer 2005
12. Gene Ontology: tool for the unification of biology. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, the Gene Ontology Consortium, Nat Genet 2000 25 25 29 10.1038/75556 10802651 (Pubitemid 30257031)
13. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Huang DW, Sherman BT, Lempicki RA, Nat Protoc 2009 4 44 57 19131956
14. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Huang DW, Sherman BT, Lempicki RA, Nucleic Acids Res 2009 37 1 13 10.1093/nar/gkn923 19033363
15. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR, Science 2006 313 1929 1935 10.1126/science.1132939 17008526 (Pubitemid 44497995)
16. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. Wen Z, Wang Z, Wang S, Ravula R, Yang L, Xu J, Wang C, Zuo Z, Chow MSS, Shi L, PLoS One 2011 6 18278 10.1371/journal.pone.0018278 21464939
17. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Zaman SN, Johnson RD, Johnson PJ, Melia WM, Portmann BC, Williams R, Lancet 1985 325 1357 1360 10.1016/S0140-6736(85)91785-4 (Pubitemid 15060907)
18. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, N Engl J Med 1993 328 1797 1801 10.1056/NEJM199306243282501 7684822 (Pubitemid 23174709)
19. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M, Gut 2001 48 251 259 10.1136/gut.48.2.251 11156649 (Pubitemid 32141852)
20. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi China. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE, Cancer Res 1989 49 2506 2539905
21. Hepatocellular carcinoma: the need for progress. Thomas MB, Zhu AX, J Clin Oncol 2005 23 2892 2899 10.1200/JCO.2005.03.196 15860847 (Pubitemid 46224106)
22. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Wang SM, Ooi LLPJ, Hui KM, Clin Cancer Res 2007 13 6275 6283 10.1158/1078-0432.CCR-06-2236 17975138 (Pubitemid 350075015)
23. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS, Hepatology 2004 40 667 676 10.1002/hep.20375 15349906 (Pubitemid 39265589)
24. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Nat Med 2003 9 416 423 10.1038/nm843 12640447 (Pubitemid 36460075)
25. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Lancet 2003 361 923 929 10.1016/S0140-6736(03)12775-4 12648972 (Pubitemid 36332108)
26. Molecular-based prediction of early recurrence in hepatocellular carcinoma. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, Umeshita K, Sakon M, Ueno N, Oba S, J Hepatol 2004 41 284 291 10.1016/j.jhep.2004.04.031 15288478 (Pubitemid 39177633)
27. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. Farinati F, Salvagnini M, De Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R, J Hepatol 1990 11 297 301 10.1016/0168-8278(90)90211- 9 1705274